Revenio published its Interim Report Q1 2026 on Tuesday, April 28, 2026. Please find result materials below.

Interim Report Q1 2026

Information page

Press conference

Revenio presented the transaction in English to the media, investors, and analysts in a press conference on April 13, 2026 at 14:00 EET. Watch the recording below.

Revenio accelerates growth and value creation by acquiring Visionix


## Welcome to Revenio's investor website

Revenio is a global leader in eye care diagnostic and vision care technology solutions operating globally. The Revenio Group offers a comprehensive portfolio of diagnostic devices, imaging solutions, refraction technologies, software and workflow solutions serving the needs of optometry, optical retail and ophthalmology.

 

Under the iCare and Visionix brands, the Group’s eye care solutions include, among others, tonometers, retinal imaging devices, OCT solutions, perimeters, refraction devices and clinical software solutions.

 

Revenio’s ambition is to build more connected and efficient eye care diagnostic workflows by providing eye care professionals with fast, easy-to-use and reliable solutions for the diagnosis and monitoring of glaucoma, retinal diseases and other eye conditions. Revenio’s solutions support eye care professionals globally by improving diagnostic efficiency, clinical workflows and quality of care throughout the patient journey.

Key figures

<p>Revenio is a global leader in ophthalmological devices and software solutions. We focus on eye care solutions; our objective is to improve the quality of clinical diagnostics with targeted product innovations and software solutions. </p><a href='/investors/as_an_investment' class='Button'><button class='Button__Element' href=''/investors/as_an_investment'>Read more</button></a>

Revenio as an investment

<p>Our updated growth strategy keeps focusing on the eye care market, aiming to improve clinical diagnostics' quality through specific product innovations.  </p><a href='/investors/as_an_investment/strategy' class='Button'><button class='Button__Element' href=''/investors/as_an_investment/strategy'>Read more</button></a>

Strategy

<p>Our corporate responsibility priorities are based on our strategic guidelines and the value we create for stakeholders, society, the environment, and the climate. </p><a href='/sustainability/sustainability_themes' class='Button'><button class='Button__Element' href='''/sustainability/sustainability_themes'>Read more</button></a>

Sustainability

<p> Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. </p><a href='/about_us/products' class='Button'><button class='Button__Element' href='''/about_us/products'>Read more</button></a>

Products

![](https://storage.googleapis.com/ir-pages-assets-fi/Revenio/elise-zimmerman-ndpRohZL6bE-unsplash.jpg)

### Outlook and guidance

See our guidance

<h2 style="color:white" color:"white">Popular links</h2>

![](https://inderes-ir-pages-prod-assets.storage.googleapis.com/reveniogroup/images/iStock-976585606-optimized.jpg)

### Investor contacts

Email: ir@revenio.fi

Thank you for your answers. We will do our best to develop our operations on the basis of this feedback.

Interim Report Q1 2026

Revenio accelerates growth and value creation by acquiring Visionix

Welcome to Revenio's investor website

Key figures

{{stockPrice}} EUR

{{stockPricePercentageChange}}

{{stockPriceLatestDate}}

109.7

MEUR

2025

23.2

%

2025

Revenio as an investment

Revenio as an investment

Outlook and guidance

Upcoming events

Releases

Latest video

Popular links

Investor contacts